"Rebound growth of infantile hemangiomas (IHs) may occur in up to a quarter of patients treated with oral propranolol (OP) therapy, and early discontinuation of therapy may double this risk, according to a new retrospective study. These findings a"...
DOSAGE AND ADMINISTRATION
Solaraze® Gel is applied to lesion areas twice daily. It is to be smoothed onto the affected skin gently. The amount needed depends upon the size of the lesion site. Assure that enough Solaraze® Gel is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site. The recommended duration of therapy is from 60 days to 90 days. Complete healing of the lesion(s) or optimal therapeutic effect may not be evident for up to 30 days following cessation of therapy. Lesions that do not respond to therapy should be carefully re-evaluated and management reconsidered.
Store at controlled room temperature 20-25°C (68-77°F); excursions permitted between 1530°C (59-86°F). Protect from heat. Avoid freezing.
Manufactured by: Almirall Hermal GmbH D-21465 Reinbek, Germany. Manufactured for: PharmaDerm, A division of Fougera, Melville, New York 11747. www.pharmaderm.com. www.solaraze.com. Revised: May 2016This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 5/23/2016
Additional Solaraze Information
Solaraze - User Reviews
Solaraze User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.